Pharmafile Logo

GSK

Jemperli®▼(dostarlimab) with platinum-based chemotherapy to be made available on the NHS for all eligible patients in England for first-line treatment of primary advanced or recurrent endometrial cancer

Jemperli (dostarlimab) with platinum-based chemotherapy to be made available on the NHS for all eligible patients in England for first-line treatment of primary advanced or recurrent endometrial cancer Following a positive recommendation from the National Institute for Health and Care Excellence (NICE), eligible patients living with primary advanced or recurrent endometrial cancer with mismatch repair...

Blenrep (belantamab mafodotin) combinations approved by UK MHRA in relapsed/refractory multiple myeloma 

Superior efficacy shown in two head-to-head phase III trials, including overall survival in DREAMM-7 Blenrep combinations could redefine treatment as early as first relapse where more effective options are needed UK approval first in the world with submissions under review in 14 markets and additional approvals expected in 2025. 17 April 2025 -- London, UK --...

GSK’s Omjjara▼ (momelotinib) is accepted for use within NHS Scotland, in line with its licence, for eligible adult myelofibrosis patients with moderate to severe anaemia

Clinicians in Scotland will now have the option to use momelotinib for the treatment of disease-related splenomegaly or symptoms in adult myelofibrosis patients with moderate to severe anaemia Momelotinib is the first JAK-inhibitor treatment to be made available on the NHS in Scotland specifically indicated for both newly diagnosed and previously ruxolitinib-treated adult myelofibrosis patients...

Jemperli (dostarlimab) becomes the first immunotherapy treatment to receive NICE recommendation for use, in line with its license, in eligible endometrial cancer patients in first line setting

This final draft guidance recommends the use of dostarlimab in combination with platinum-containing chemotherapy for the treatment of adult patients with mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) primary advanced or recurrent endometrial cancer and who are candidates for systemic therapy Following a positive recommendation from the National Institute for Health and Care Excellence (NICE), approximately...

NICE has issued guidance for GSK’s Omjjara (momelotinib) as a treatment option for disease-related splenomegaly or symptoms in adult myelofibrosis patients with moderate to severe anaemia

Myelofibrosis is a rare blood cancer that can result in the progressive scarring of bone marrow (fibrosis), impairing its normal function There are approximately 1,970 people living with myelofibrosis across England, Wales and Northern Ireland Momelotinib is the first JAK-inhibitor treatment to be made available in England and Wales for both newly diagnosed and previously...

Medicines and Healthcare Products Regulatory Agencyauthorises GSK’s Omjjara (momelotinib) in Great Britainfor treating splenomegaly or symptoms in adultmyelofibrosis patients with moderate to severe anaemia

First JAK inhibitor treatment in Great Britain specifically indicated for both newly diagnosed and previously treated myelofibrosis patients with moderate to severe anaemia 31 January 2024 -- Middlesex, UK -- GSK plc today announced that Omjjara (momelotinib) was granted Marketing Authorisation (MA) in Great Britain (GB) by the Medicines and Healthcare products Regulatory Agency (MHRA)...

GSK Completes Acquisition of Sierra Oncology

London, UK, 1 July, 2022: GSK plc (LSE/NYSE: GSK) today announced it has completed the acquisition of Sierra Oncology, Inc. (Sierra Oncology), a California-based biopharmaceutical company focused on targeted therapies for the treatment of rare forms of cancer. The acquisition was approved by Sierra Oncology's shareholders on 29 June 2022.
https://www.gsk.com/en-gb/
980 Great West Rd, London TW8 9GS